Verge Genomics Announces Artificial Intelligence-Enabled Drug Discovery Collaboration with Alexion for Rare Neurodegenerative and Neuromuscular Diseases Press ReleaseRob MaguireSeptember 8, 2023
The CEO of Verge Genomics shares how she's overcome gender and age biases in biotech by showing people 'there can be a new way of doing things' NewsRob MaguireAugust 18, 2023
The 30 young leaders who are forging a new future for the healthcare industry in 2023 NewsRob MaguireAugust 17, 2023
At ENCALS, Commitment to Understanding the Cause of ALS and developing effective Treatments Rob MaguireJuly 18, 2023
CMO Diego Cadavid, M.D. to present data for Phase 1 of VRG50635 at ENCALS 2023 EventsRob MaguireJuly 13, 2023
Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Press ReleaseRob MaguireJune 15, 2023
Verge Genomics to Present at Mass General Brigham & Bank of America World Medical Innovation Forum Press ReleaseRob MaguireJune 6, 2023
Verge Genomics to Incorporate Emerald Digital Health Technology into its ALS Phase 1b Proof-of-Concept Clinical Trial Press ReleaseRob MaguireMay 23, 2023
Verge Genomics to Present at 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023 Press ReleaseRob MaguireJanuary 4, 2023
Verge Genomics Appoints Diego Cadavid, M.D., as Chief Medical Officer Press ReleaseRob MaguireDecember 6, 2022
